Online inquiry

IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5409MR)

This product GTTS-WQ5409MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD2 gene. The antibody can be applied in Psoriasis, severe chronic plaque research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001328609.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 914
UniProt ID P06729
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ5409MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11516MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ12647MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ15153MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ10652MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ10218MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ9847MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ9646MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ8567MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW